ResearcherTongji UniversityNo recent work listed

Ling Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2290-3756; OpenAlex author ID A5101849153. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper

Papers 3

Development of a lipid metabolism-related gene model to predict prognosis in patients with pancreatic cancer. Co-author DOI 10.12998/wjcc.v9.i35.10884 ↗
Differences in lipidomics may be potential biomarkers for early diagnosis of pancreatic cancer. Last author DOI 10.1590/s0102-865020200050000008 ↗
YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine. Co-author DOI 10.3390/biom9100620 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hong Xu · 2 shared papers, 2020–2021 · strength 0.25
- Paper Development of a lipid metabolism-related gene model to predict prognosis in patients with pancreatic cancer. DOI 10.12998/wjcc.v9.i35.10884 ↗
- Paper Differences in lipidomics may be potential biomarkers for early diagnosis of pancreatic cancer. DOI 10.1590/s0102-865020200050000008 ↗
Xinyu Wang · 1 shared paper, 2021 · strength 0.15
- Paper Development of a lipid metabolism-related gene model to predict prognosis in patients with pancreatic cancer. DOI 10.12998/wjcc.v9.i35.10884 ↗
Maolei Xu · 1 shared paper, 2019 · strength 0.11
- Paper YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabin… DOI 10.3390/biom9100620 ↗
Dehua Zhou · 1 shared paper, 2020 · strength 0.10
- Paper Differences in lipidomics may be potential biomarkers for early diagnosis of pancreatic cancer. DOI 10.1590/s0102-865020200050000008 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.